TR200501460T3 - Onkolitik virüsler kullanarak ağrı azaltma yöntemi - Google Patents

Onkolitik virüsler kullanarak ağrı azaltma yöntemi

Info

Publication number
TR200501460T3
TR200501460T3 TR2005/01460T TR200501460T TR200501460T3 TR 200501460 T3 TR200501460 T3 TR 200501460T3 TR 2005/01460 T TR2005/01460 T TR 2005/01460T TR 200501460 T TR200501460 T TR 200501460T TR 200501460 T3 TR200501460 T3 TR 200501460T3
Authority
TR
Turkey
Prior art keywords
mammal
oncolytic viruses
reduction method
pain reduction
oncolytic
Prior art date
Application number
TR2005/01460T
Other languages
English (en)
Inventor
Morris Donald
C. Coffey Matthew
G. Thompson Bradley
Original Assignee
Oncolytics Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech, Inc. filed Critical Oncolytics Biotech, Inc.
Publication of TR200501460T3 publication Critical patent/TR200501460T3/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut bulus, bir memelide neoplazmalar ile baglantili agrinin azaltilmasina yönelik, etkin miktarda bir veya daha fazla onkolitik virüsün uygulanmasini kapsayan bir yöntem saglar. Tercihen memeli, bir analjezik de alir ve memelinin ihtiyaç duydugu analjezik miktari, onkolitik virüs uygulandiginda azalir. Onkolitik virüs tercihen reovirüstür. Memeli ayrica kemoterapiye, immünoterapiye, hormonal terapiye ve/veya radyasyon terapisine de tabi tutulabilir.
TR2005/01460T 2002-05-09 2003-05-07 Onkolitik virüsler kullanarak ağrı azaltma yöntemi TR200501460T3 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37867502P 2002-05-09 2002-05-09
US44317703P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
TR200501460T3 true TR200501460T3 (tr) 2005-06-21

Family

ID=29423642

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2005/01460T TR200501460T3 (tr) 2002-05-09 2003-05-07 Onkolitik virüsler kullanarak ağrı azaltma yöntemi

Country Status (19)

Country Link
US (2) US20040091458A1 (tr)
EP (1) EP1505992B1 (tr)
JP (1) JP5241059B2 (tr)
AR (1) AR039986A1 (tr)
AT (1) ATE404213T1 (tr)
AU (1) AU2003229431B8 (tr)
BR (1) BR0309825A (tr)
CA (1) CA2484398C (tr)
DE (2) DE03722131T1 (tr)
DK (1) DK1505992T3 (tr)
ES (1) ES2239928T3 (tr)
IL (1) IL164695A (tr)
MX (1) MXPA04011007A (tr)
NZ (1) NZ536102A (tr)
PT (1) PT1505992E (tr)
SI (1) SI1505992T1 (tr)
TR (1) TR200501460T3 (tr)
TW (1) TWI316405B (tr)
WO (1) WO2003094938A1 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int WEAKEN REOVIRUS
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
KR20100054358A (ko) * 2008-11-14 2010-05-25 김재은 스틱 연고
AR076540A1 (es) * 2009-05-01 2011-06-22 Eurand Inc Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
EP2383577A1 (en) * 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
WO2017037523A1 (en) * 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization
EA201891848A1 (ru) * 2016-02-16 2019-02-28 Осака Юниверсити Фармацевтическая композиция для применения в лечении фиброза

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
JP2001519175A (ja) * 1997-10-09 2001-10-23 プロ − バイラス，インコーポレイテッド ウイルスを用いた新生物の処置
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
JP2005526124A (ja) 2005-09-02
IL164695A0 (en) 2005-12-18
DE03722131T1 (de) 2005-09-15
MXPA04011007A (es) 2005-02-14
TWI316405B (en) 2009-11-01
ES2239928T3 (es) 2009-02-16
NZ536102A (en) 2008-01-31
TW200402305A (en) 2004-02-16
HK1070565A1 (en) 2005-06-24
ATE404213T1 (de) 2008-08-15
AR039986A1 (es) 2005-03-09
AU2003229431B8 (en) 2009-07-02
CA2484398C (en) 2014-01-21
DE60322885D1 (de) 2008-09-25
US20040091458A1 (en) 2004-05-13
IL164695A (en) 2010-12-30
US20080081032A1 (en) 2008-04-03
AU2003229431A1 (en) 2003-11-11
PT1505992E (pt) 2008-10-06
BR0309825A (pt) 2005-03-01
AU2003229431B2 (en) 2008-01-17
JP5241059B2 (ja) 2013-07-17
DK1505992T3 (da) 2008-10-06
EP1505992A1 (en) 2005-02-16
WO2003094938A1 (en) 2003-11-20
SI1505992T1 (sl) 2009-02-28
EP1505992B1 (en) 2008-08-13
ES2239928T1 (es) 2005-10-16
CA2484398A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
TR200501460T3 (tr) Onkolitik virüsler kullanarak ağrı azaltma yöntemi
AR059482A1 (es) Uso de supresion inmune local para potenciar terapia viral oncolitica
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
AR032912A1 (es) Formulacion farmaceutica
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
NO20054988D0 (no) Preparater og metoder for behandling av cancer
PL371736A1 (en) Method for administering glp-1 molecules
CY1115649T1 (el) Σκευασματα ινσουλινων μακρας-δρασης
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
NZ589719A (en) Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
PT933993E (pt) Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
BRPI0509177A (pt) uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
NO20051654L (no) Forlenget frigjoring av farmasoytisk preparat
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
TR200001293T2 (tr) Uykuda solunum durmasını tedavi etmek için mirtazapin kullanımı
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
ATE285247T1 (de) Krebstherapie mit lymphotoxin
EA201101036A1 (ru) Применение хлорида аммония в терапии